A CRISPR-based diagnostic tool to survey drug resistance in human African trypanosomiasis.

ABSTRACT: The World Health Organization aims to eliminate human African trypanosomiasis caused by Trypanosoma brucei gambiense (gHAT) by 2030. With the decline of reported cases, maintaining active surveillance is essential, including for the potential emergence of drug-resistant parasites. We have developed new highly specific diagnostic tools, using the Cas13a-based Specific High-Sensitivity Reporter Enzymatic UnLOCKing (SHERLOCK) technology, for the detection of drug-resistant genotypes that (i) are already circulating, such as the AQP2/3₍₈₁₄₎ chimera providing resistance to pentamidine and melarsoprol or (ii) could emerge, such as the TbCPSF3 (N²³²H) mutation, associated with acoziborole resistance under laboratory conditions. The AQP2/3₍₈₁₄₎

SUBMITTER: Perez Anton E 

PROVIDER: S-EPMC12691586 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature